Komori
Sumitomo Pharma (4506) · PolicyFirst stated

Ensuring the reliability and transparency of financial reporting and responding to inaccurate information

First written in 2026-08-07. . Latest entry: 2026-08-07.

1entries
1years
1from disclosures
Share on X
How it moved
Same theme, other companies

This thread is not in a theme yet. When the same subject shows up in other companies' filings, you can compare them here.

Full recordFilings, disclosures and news, newest first
  1. 2026-08-07First statedOccurring Fact

    「We will continue working to ensure the reliability and transparency of our financial reporting and provide investors with timely and appropriate disclosure.」

    In response to claims in an external report, the company explained the accounting treatment of gains on the transfer of interests in affiliates, accounts receivable, dividends from subsidiaries and intra-group transactions. It also presented, for the first time as a standalone theme, its response policy, including internal approval, verification and review systems, an unqualified audit opinion from the accounting auditor and legal action where necessary.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Sumitomo Pharma yet. It last moved in the Occurring Fact of 2026-08-07: "First stated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Ensuring the reliability and transparency of financial reporting and responding to inaccurate information | Sumitomo Pharma Co.,Ltd. (4506) | Komori